Bridges Investment Management Inc. Raises Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Bridges Investment Management Inc. boosted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 137.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 158,591 shares of the medical equipment provider’s stock after acquiring an additional 91,916 shares during the period. Intuitive Surgical accounts for about 1.1% of Bridges Investment Management Inc.’s investment portfolio, making the stock its 27th largest holding. Bridges Investment Management Inc.’s holdings in Intuitive Surgical were worth $70,549,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of ISRG. Capital Research Global Investors purchased a new position in Intuitive Surgical during the 1st quarter valued at about $374,390,000. Coatue Management LLC lifted its position in Intuitive Surgical by 65.7% during the 4th quarter. Coatue Management LLC now owns 1,301,595 shares of the medical equipment provider’s stock valued at $439,106,000 after acquiring an additional 516,054 shares during the period. Vanguard Group Inc. lifted its position in Intuitive Surgical by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after acquiring an additional 493,126 shares during the period. Edgewood Management LLC lifted its position in Intuitive Surgical by 7.9% during the 4th quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock valued at $1,731,016,000 after acquiring an additional 374,667 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in Intuitive Surgical by 51.2% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 893,341 shares of the medical equipment provider’s stock valued at $356,524,000 after acquiring an additional 302,382 shares during the period. 83.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on ISRG shares. Robert W. Baird lifted their target price on shares of Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a report on Friday, July 19th. Barclays lifted their target price on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a report on Thursday, July 18th. JPMorgan Chase & Co. lifted their target price on shares of Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a report on Friday, July 19th. Stifel Nicolaus lifted their target price on shares of Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a report on Friday, July 19th. Finally, Citigroup lifted their target price on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $446.45.

Insider Activity at Intuitive Surgical

In related news, Director Craig H. Barratt sold 1,400 shares of the business’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total transaction of $641,382.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Intuitive Surgical news, EVP Myriam Curet sold 2,818 shares of the company’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total value of $1,291,010.34. Following the completion of the transaction, the executive vice president now directly owns 298 shares in the company, valued at $136,522.74. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Craig H. Barratt sold 1,400 shares of the company’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $641,382.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 53,120 shares of company stock worth $25,528,753. 0.90% of the stock is owned by company insiders.

Intuitive Surgical Trading Up 1.6 %

Shares of NASDAQ ISRG opened at $490.01 on Friday. The firm has a 50 day moving average of $467.17 and a 200 day moving average of $424.26. The firm has a market capitalization of $173.81 billion, a price-to-earnings ratio of 88.45, a price-to-earnings-growth ratio of 5.41 and a beta of 1.39. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $496.18.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.24. The company had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same period in the previous year, the business posted $1.18 earnings per share. Sell-side analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.